NCT00856310

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Tolerability of REGN475 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled single-dose study of the safety and tolerability of intravenously administered REGN475 in healthy volunteers. The primary objective of the study is to assess the safety and tolerability of REGN475. The secondary objectives are to characterize the pharmacokinetic and immunogenicity profiles of REGN475.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	REGN475 (SAR164877)	Subcutaneous administration REGN475 (SAR164877)

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2009-03-05
• Last updated: 2012-05-10

Locations

1 site across 1 country: United States